Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878544 | 0.81 | CYP19A1 (0.39) | CES1CYP3A4CYP1A2LMNAADRA1D | |
| SCHEMBL6249759 | 0.81 | CYP19A1 (0.39) | CES1CYP3A4CYP1A2LMNAADRA1D | |
| SCHEMBL11778468 | 0.81 | CYP19A1 (0.49) | CES1NFKB1NPC1RAB9AMAPT | |
| SCHEMBL8921555 | 0.78 | CES1 (0.52) | CES1SLC6A2CYP3A4CYP1A2RET | |
| SCHEMBL19428057 | 0.78 | MIF (0.40) | CES1ADRA1DADRA1ACHRM1MEN1 | |
| SCHEMBL30436624 | 0.75 | CES1 (0.65) | CES1PARP1NPC1TSHRRAB9A | |
| SCHEMBL5921441 | 0.74 | CYP19A1 (0.51) | LMNATP53NFKB1NPC1TSHR | |
| SCHEMBL20153618 | 0.74 | MEN1 (0.39) | CHRM1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL4040169 | 0.73 | CES1 (0.50) | CES1SLC6A2CYP3A4CYP1A2RET | |
| SCHEMBL8859036 | 0.73 | CES1 (0.56) | CES1SLC6A2CYP3A4CYP1A2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2004-11-18 | — | — | US | disclosed |
| US-6723731-B2 | 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY | NOVO NORDISK A/S (DK) | 2004-04-20 | — | — | US | disclosed |
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | disclosed |
| US-6602901-B2 | Antidiabetic agents, obesity | NOVO NORDISK A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6407127-B2 | 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY | NOVO NORDISK A/S (DK) | 2002-06-18 | — | — | US | disclosed |
| US-6353018-B1 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010031764-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| US-20010031762-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| EP-1123268-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| EP-1123269-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| US-6248781-B1 | ANTIDIABETIC AGENTS; DIETETICS | NOVO NORDISK A/S (DK) | 2001-06-19 | — | — | US | disclosed |
| US-6214820-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | NOVO NORDISK A/S (DK) | 2001-04-10 | — | — | US | disclosed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023416-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| EP-0094560-B1 | PROCESS FOR THE PRODUCTION OF 3-(10,11-DIHYDRO-5H-DIBENZO(A,D)-CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-1-PROPANEAMINE-N-OXIDE | A. Nattermann & Cie. GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031762-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | CES1 195/4885SLC6A2 4513/4885CYP3A4 1781/4885 |
| US-20020115654-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | CES1 58/4885SLC6A2 4695/4885CYP3A4 616/4885 |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | CES1 195/4885SLC6A2 4513/4885CYP3A4 1781/4885 |
| US-20010031764-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) | PPARG, PPARA, PPARD | CES1 195/4885SLC6A2 4513/4885CYP3A4 1781/4885 |
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | CES1 195/4885SLC6A2 4513/4885CYP3A4 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.